aspirin has been researched along with Embryopathies in 21 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Excerpt | Relevance | Reference |
---|---|---|
"Indications for aspirin during pregnancy are a matter of debate and there is a recent trend to an extended prescription and an overuse of aspirin in pregnancy." | 9.01 | [Aspirin and preeclampsia]. ( Atallah, A; Doret-Dion, M; Gaucherand, P; Goffinet, F; Lecarpentier, E; Tsatsaris, V, 2019) |
"Self-reported use or consumption of tobacco, marijuana, cocaine, aspirin, and other nonsteroidal antiinflammatory drugs during pregnancy." | 7.69 | Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. ( Allred, EN; Cohen, A; Epstein, MF; Leviton, A; Pagano, M; Sullivan, KF; Van Marter, LJ, 1996) |
"Indications for aspirin during pregnancy are a matter of debate and there is a recent trend to an extended prescription and an overuse of aspirin in pregnancy." | 5.01 | [Aspirin and preeclampsia]. ( Atallah, A; Doret-Dion, M; Gaucherand, P; Goffinet, F; Lecarpentier, E; Tsatsaris, V, 2019) |
"The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during their first pregnancy improved the outcome of gestation hypertensive disorders." | 3.77 | Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. ( Bakhti, A; Vaiman, D, 2011) |
"The prevention of preeclampsia currently relies on low-dose aspirin started at the beginning of pregnancy." | 3.72 | [Prevention of preeclampsia]. ( Desvaux, D; Haddad, B, 2003) |
"Self-reported use or consumption of tobacco, marijuana, cocaine, aspirin, and other nonsteroidal antiinflammatory drugs during pregnancy." | 3.69 | Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. ( Allred, EN; Cohen, A; Epstein, MF; Leviton, A; Pagano, M; Sullivan, KF; Van Marter, LJ, 1996) |
"Over-the-counter antipyretics (acetaminophen, aspirin, ibuprofen) and/or analgesics (acetaminophen, aspirin, diclofenac, ibuprofen, naproxen) are relatively safe for adults." | 2.48 | [Developmental toxicity of the over-the-counter analgetics and antypiretics]. ( Burdan, F; Cendrowska-Pinkosz, M; Dworzańska, A; Dworzański, W; Kubiatowski, T; Starosławska, E; Szumiło, J; Urbańczyk-Zawadzka, M, 2012) |
"If diagnosed and treated early in pregnancy with low-dose aspirin and subcutaneous heparin the outlook for a successful pregnancy is much improved." | 2.41 | A literature review on the antiphospholipid syndrome and the effect on childbearing. ( Vials, JM, 2001) |
"We estimated the proportion of miscarriage to be almost doubled, whereas there was no increased risk of congenital abnormalities or prematurity in women exposed to a drug overdose compared with the background population." | 1.31 | Pregnancy outcome after suicide attempt by drug use: a Danish population-based study. ( Flint, C; Larsen, H; Nielsen, GL; Olsen, J; Sørensen, HT, 2002) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (28.57) | 18.7374 |
1990's | 5 (23.81) | 18.2507 |
2000's | 7 (33.33) | 29.6817 |
2010's | 3 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Atallah, A | 1 |
Lecarpentier, E | 1 |
Goffinet, F | 2 |
Gaucherand, P | 1 |
Doret-Dion, M | 1 |
Tsatsaris, V | 1 |
Bakhti, A | 1 |
Vaiman, D | 1 |
Burdan, F | 1 |
Starosławska, E | 1 |
Szumiło, J | 1 |
Dworzańska, A | 1 |
Dworzański, W | 1 |
Kubiatowski, T | 1 |
Cendrowska-Pinkosz, M | 1 |
Urbańczyk-Zawadzka, M | 1 |
PETROV-MASLAKOV, MA | 1 |
Desvaux, D | 1 |
Haddad, B | 1 |
Nitsch, P | 1 |
Breuer, J | 1 |
Geipel, A | 1 |
Bartmann, P | 1 |
Gembruch, U | 1 |
Heep, A | 1 |
Iwashita, T | 1 |
Fujitani, M | 1 |
Yamamoto, Y | 1 |
Katsurada, T | 1 |
Yoshida, Y | 1 |
Aguilera, C | 1 |
Agustí, A | 1 |
Srivastava, AR | 1 |
Modi, P | 1 |
Sahi, S | 1 |
Niwariya, Y | 1 |
Singh, H | 1 |
Banerjee, A | 1 |
Soller, RW | 1 |
Stander, H | 1 |
Van Marter, LJ | 1 |
Leviton, A | 1 |
Allred, EN | 1 |
Pagano, M | 1 |
Sullivan, KF | 1 |
Cohen, A | 1 |
Epstein, MF | 1 |
Bréart, G | 1 |
Uzan, S | 1 |
Wakatsuki, A | 1 |
Izumiya, C | 1 |
Okatani, Y | 1 |
Sagara, Y | 1 |
Vials, JM | 1 |
Flint, C | 1 |
Larsen, H | 1 |
Nielsen, GL | 1 |
Olsen, J | 1 |
Sørensen, HT | 1 |
Ginsberg, JS | 1 |
Hirsh, J | 1 |
Raub, W | 1 |
Lubbe, WF | 1 |
Liggins, GC | 1 |
Wilson, JG | 1 |
Fisch, L | 1 |
Warkany, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 189 |
Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1078 |
Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 78 |
Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 303 |
Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 134 |
Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 141 |
Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 42 |
Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 352 |
Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 264 |
Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 668 |
Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1506 |
Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 214 |
Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 26 |
Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 54 |
Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 9 |
Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 23 |
Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 290 |
Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 8 |
Placebo Arm | 21 |
7 reviews available for aspirin and Embryopathies
Article | Year |
---|---|
[Aspirin and preeclampsia].
Topics: Aspirin; Chronobiology Phenomena; Contraindications, Drug; Cyclooxygenase Inhibitors; Drug Utilizati | 2019 |
[Developmental toxicity of the over-the-counter analgetics and antypiretics].
Topics: Adult; Analgesics; Antipyretics; Aspirin; Female; Fetal Diseases; Humans; Infant, Newborn; Infant, N | 2012 |
Anticoagulation for pregnant patients with mechanical heart valves.
Topics: Abortion, Spontaneous; Anticoagulants; Aspirin; Drug Administration Schedule; Female; Fetal Diseases | 2007 |
A literature review on the antiphospholipid syndrome and the effect on childbearing.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Embolism; Female; Fetal Death; Fetal Diseases; F | 2001 |
Use of antithrombotic agents during pregnancy.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fetal Diseases; Hemorrhage; Humans; Oste | 1992 |
Lupus anticoagulant and pregnancy.
Topics: Aspirin; Autoantibodies; Blood Coagulation Factors; Female; Fetal Death; Fetal Diseases; Fetal Growt | 1985 |
Present status of drugs as teratogens in man.
Topics: Abnormalities, Drug-Induced; Alkylating Agents; Anti-Bacterial Agents; Anticonvulsants; Antiemetics; | 1973 |
14 other studies available for aspirin and Embryopathies
Article | Year |
---|---|
Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation.
Topics: Adult; Aspirin; Birth Weight; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Fetal | 2011 |
[PRENATAL PROTECTION OF THE FETUS AND PROBLEMS OF DRUG THERAPY IN PREGNANCY].
Topics: Adrenal Cortex Hormones; Aminopyrine; Anti-Bacterial Agents; Aspirin; Drug Therapy; Female; Fetal Di | 1964 |
[Prevention of preeclampsia].
Topics: Adult; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fetal Diseas | 2003 |
Dilatation of the abdominal umbilical vein is associated with increased risk of thrombotic complications.
Topics: Abdomen; Adult; Aspirin; Dilatation, Pathologic; Female; Fetal Diseases; Fibrinolytic Agents; Hepari | 2006 |
Interferon-alfa treatment of essential thrombocythemia during pregnancy.
Topics: Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Fetal Diseases; Humans; Immunolog | 2006 |
[Low dose of aspirin during pregnancy].
Topics: Abnormalities, Drug-Induced; Abortion, Habitual; Abortion, Spontaneous; Adult; Animals; Anti-Inflamm | 2007 |
Maternal drug exposure and perinatal intracranial hemorrhage.
Topics: Aspirin; Cerebral Hemorrhage; Female; Fetal Diseases; Humans; Infant, Newborn; Infant, Newborn, Dise | 1981 |
Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cocaine; Confounding | 1996 |
ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women.
Topics: Aspirin; Female; Fetal Diseases; Humans; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Compl | 1996 |
Oxidative damage in fetal rat brain induced by ischemia and subsequent reperfusion. Relation to arachidonic acid peroxidation.
Topics: Animals; Arachidonic Acid; Aspirin; Brain; Cyclooxygenase Inhibitors; Disease Models, Animal; Female | 1999 |
Pregnancy outcome after suicide attempt by drug use: a Danish population-based study.
Topics: Abortion, Spontaneous; Acetaminophen; Adolescent; Adult; Aspirin; Child; Child, Preschool; Denmark; | 2002 |
From the National Institutes of Health.
Topics: Aspirin; Breast Neoplasms; Female; Fetal Diseases; Heart Defects, Congenital; Humans; Immunotherapy; | 1990 |
The selective and differential vulnerability of the auditory system. In: Sensorineural hearing loss.
Topics: Aspirin; Auditory Pathways; Central Nervous System; Cochlea; Deafness; Diseases in Twins; Ear; Facia | 1970 |
Experimental teratology and pediatrics.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Congenital Abnormalities; Female; Fetal Diseases; Mam | 1970 |